PBAC's latest decision on Tamsulosin hydrochloride: Recommended with restriction (2010). Considered for Lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
PBAC outcome
Recommended with restriction
Unrestricted
ICER (AUD/QALY)
$45k/QALY
$15k/QALY–$45k/QALY · across 3 submissions
Submissions
3
first 2008
Submissions
3
2008 → 2010
Eligible population
patients with lower urinary tract symptoms due to benign prostatic hyperplasia
Therapy area
Urology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
other
Comparator
prazosin
Economic model
Cost-minimisation
Eligible patients/year
100,000
ICER basis
Range aggregates 3 submissions (2008–2010) — not a single base case.
Submission history
Mar 2008: Not recommended — ICER $75k/QALY
Nov 2008: Not recommended · Restricted — ICER $75k/QALY
Nov 2010: Recommended with restriction · Unrestricted — ICER $45k/QALY